Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy CLLS?
Source: Globenewswire
- Clinical Trial Progress: Cellectis initiated the pivotal Phase 2 BALLI-01 trial for lasme-cel in October 2025, with the first interim analysis expected in Q4 2026 involving 40 participants, showcasing the company's strong growth potential in tumor immunotherapy.
- Impressive Efficacy Data: Lasme-cel achieved a 100% overall response rate and a 56% complete remission rate in the target Phase 2 population, with 80% of patients reaching minimal residual disease-negative status, indicating significant efficacy in treating relapsed acute lymphoblastic leukemia (B-ALL).
- Deepening Strategic Partnerships: Cellectis is advancing its collaboration with AstraZeneca to develop up to 10 novel cell and gene therapy products addressing high unmet medical needs, further solidifying its leadership position in the biotechnology sector.
- Sufficient Cash Runway: Cellectis believes its cash and cash equivalents will fund operations into H2 2027, ensuring continued progress in critical clinical trials and strategic investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLLS
Wall Street analysts forecast CLLS stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.420
Low
4.00
Averages
7.00
High
9.00
Current: 4.420
Low
4.00
Averages
7.00
High
9.00
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
- Manufacturing Capability Assessment: Autolus will evaluate Cellares' Cell Shuttle platform to enhance its commercial manufacturing operations at the Nucleus facility in Stevenage, UK, which is expected to improve production efficiency and reduce costs.
- High-Throughput Production: Cellares' platform can process up to 16 patient batches simultaneously, delivering up to 10-fold higher throughput than conventional cell therapy manufacturing facilities, potentially significantly enhancing Autolus' market competitiveness.
- Exploration of New Indications: Autolus is assessing its AUCATZYL® therapy for indications beyond acute lymphoblastic leukemia, and successful expansion could lead to increased demand for manufacturing capacity.
- Strategic Partnership Outlook: The integration of Cellares' technology with Autolus' existing manufacturing foundation may provide a capital-efficient solution for future expansion, addressing the growing patient demand.
See More
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Cellectis Stock Decline: Shares of Cellectis S.A. fell 17.35% following a favorable arbitration outcome for Allogene Therapeutics, which confirmed Allogene's control over the CAR-T therapy cema-cel.
Arbitration Outcome Details: The tribunal dismissed Cellectis's claims against Servier, including financial claims related to milestone payments, and mandated a partial termination of the license concerning the discontinued UCART19 V1 product.
Allogene's Future Prospects: With the legal dispute resolved, Allogene is positioned for a significant catalyst period in 2026, including an interim analysis of cema-cel's efficacy in treating large B-cell lymphoma.
Current Stock Prices: As of the latest update, Cellectis stock is priced at $3.96, while Allogene stock is at $1.49, reflecting a 1.37% increase for Allogene.
See More
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures falling approximately 0.2% on Tuesday morning.
Lightwave Logic Inc: Shares of Lightwave Logic Inc dropped 14.5% to $3.22 in pre-market trading following the announcement of a $35 million public offering.
Other Declining Stocks: Several other stocks also saw declines in pre-market trading, including Ascent Solar Technologies (-15.1%), Fractyl Health (-10.4%), and Ready Capital (-9%).
Market Overview: The overall market sentiment appears negative, with multiple companies reporting significant drops in their stock prices ahead of the trading day.
See More
Allogene Secures Full Global Control of Cema-Cel Following Arbitration Ruling
- Favorable Arbitration Outcome: Allogene's victory in arbitration with Cellectis reaffirms its full control over Cema-Cel in the U.S., EU, and UK, paving the way for global commercialization rights and enhancing market competitiveness.
- Clarified Financial Obligations: The ruling dismissed Cellectis's financial claims, establishing that milestone payments are only due upon FDA acceptance of a Biologics License Application, thereby reducing Allogene's financial burden.
- Clinical Trial Progress: Allogene is on track to conduct an interim futility analysis of Cema-Cel in the pivotal ALPHA3 trial in 1H 2026, marking significant advancement in the large B-cell lymphoma space and potentially accelerating product development.
- Optimistic Strategic Outlook: With legal matters resolved, Allogene enters 2026 poised for a critical catalyst period, expected to accelerate innovation and market penetration in the CAR T cell therapy sector.
See More
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
- Manufacturing Capability Assessment: Autolus will evaluate Cellares' Cell Shuttle platform to enhance its commercial manufacturing operations at the Nucleus facility in Stevenage, UK, which is expected to improve production efficiency and reduce costs.
- High-Throughput Production: Cellares' platform can process up to 16 patient batches simultaneously, delivering up to 10-fold higher throughput than conventional cell therapy manufacturing facilities, potentially significantly enhancing Autolus' market competitiveness.
- Exploration of New Indications: Autolus is assessing its AUCATZYL® therapy for indications beyond acute lymphoblastic leukemia, and successful expansion could lead to increased demand for manufacturing capacity.
- Strategic Partnership Outlook: The integration of Cellares' technology with Autolus' existing manufacturing foundation may provide a capital-efficient solution for future expansion, addressing the growing patient demand.
See More
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Cellectis Stock Decline: Shares of Cellectis S.A. fell 17.35% following a favorable arbitration outcome for Allogene Therapeutics, which confirmed Allogene's control over the CAR-T therapy cema-cel.
Arbitration Outcome Details: The tribunal dismissed Cellectis's claims against Servier, including financial claims related to milestone payments, and mandated a partial termination of the license concerning the discontinued UCART19 V1 product.
Allogene's Future Prospects: With the legal dispute resolved, Allogene is positioned for a significant catalyst period in 2026, including an interim analysis of cema-cel's efficacy in treating large B-cell lymphoma.
Current Stock Prices: As of the latest update, Cellectis stock is priced at $3.96, while Allogene stock is at $1.49, reflecting a 1.37% increase for Allogene.
See More
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are down, with Dow futures falling approximately 0.2% on Tuesday morning.
Lightwave Logic Inc: Shares of Lightwave Logic Inc dropped 14.5% to $3.22 in pre-market trading following the announcement of a $35 million public offering.
Other Declining Stocks: Several other stocks also saw declines in pre-market trading, including Ascent Solar Technologies (-15.1%), Fractyl Health (-10.4%), and Ready Capital (-9%).
Market Overview: The overall market sentiment appears negative, with multiple companies reporting significant drops in their stock prices ahead of the trading day.
See More
Allogene Secures Full Global Control of Cema-Cel Following Arbitration Ruling
- Favorable Arbitration Outcome: Allogene's victory in arbitration with Cellectis reaffirms its full control over Cema-Cel in the U.S., EU, and UK, paving the way for global commercialization rights and enhancing market competitiveness.
- Clarified Financial Obligations: The ruling dismissed Cellectis's financial claims, establishing that milestone payments are only due upon FDA acceptance of a Biologics License Application, thereby reducing Allogene's financial burden.
- Clinical Trial Progress: Allogene is on track to conduct an interim futility analysis of Cema-Cel in the pivotal ALPHA3 trial in 1H 2026, marking significant advancement in the large B-cell lymphoma space and potentially accelerating product development.
- Optimistic Strategic Outlook: With legal matters resolved, Allogene enters 2026 poised for a critical catalyst period, expected to accelerate innovation and market penetration in the CAR T cell therapy sector.
See More
